Comment on Galapagos Cozies Up Closer to Gilead Sciences

Galapagos Cozies Up Closer to Gilead Sciences

Gilead Sciences (NASDAQ: GILD) inked a collaboration deal with Galapagos NV (NASDAQ: GLPG) in 2015 to gain rights to the latter's JAK1 inhibitor filgotinib. Today, Galapagos decided to execute its co-commercialization rights to filgotinib in several European countries. The move comes only weeks ahead of a standstill agreement between the two companies expires and positions Galapagos to split profit in regions covered by the co-marketing agreement.

 

Comment On This Story

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News